Cargando…

Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity

Lung cancer is one of the main cancer types due to its persistently high incidence and mortality, yet a simple and effective prognostic model is still lacking. This study aimed to identify independent prognostic genes related to the heterogeneity of lung adenocarcinoma (LUAD), generate a prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Pengdou, Zhang, Huojun, Jiang, Weiling, Wang, Lingling, Liu, Lu, Zhou, Yuhao, Zhou, Ling, Liu, Huiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035852/
https://www.ncbi.nlm.nih.gov/pubmed/35480896
http://dx.doi.org/10.3389/fmolb.2022.807497
_version_ 1784693390694154240
author Zheng, Pengdou
Zhang, Huojun
Jiang, Weiling
Wang, Lingling
Liu, Lu
Zhou, Yuhao
Zhou, Ling
Liu, Huiguo
author_facet Zheng, Pengdou
Zhang, Huojun
Jiang, Weiling
Wang, Lingling
Liu, Lu
Zhou, Yuhao
Zhou, Ling
Liu, Huiguo
author_sort Zheng, Pengdou
collection PubMed
description Lung cancer is one of the main cancer types due to its persistently high incidence and mortality, yet a simple and effective prognostic model is still lacking. This study aimed to identify independent prognostic genes related to the heterogeneity of lung adenocarcinoma (LUAD), generate a prognostic risk score model, and construct a nomogram in combination with other pathological characteristics to predict patients’ overall survival (OS). A significant amount of data pertaining to single-cell RNA sequencing (scRNA-seq), RNA sequencing (RNA-seq), and somatic mutation were used for data mining. After statistical analyses, a risk scoring model was established based on eight independent prognostic genes, and the OS of high-risk patients was significantly lower than that of low-risk patients. Interestingly, high-risk patients were more sensitive and effective to immune checkpoint blocking therapy. In addition, it was noteworthy that CCL20 not only affected prognosis and differentiation of LUAD but also led to poor histologic grade of tumor cells. Ultimately, combining risk score, clinicopathological information, and CCL20 mutation status, a nomogram with good predictive performance and high accuracy was established. In short, our research established a prognostic model that could be used to guide clinical practice based on the constantly updated big multi-omics data. Finally, this analysis revealed that CCL20 may become a potential therapeutic target for LUAD.
format Online
Article
Text
id pubmed-9035852
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90358522022-04-26 Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity Zheng, Pengdou Zhang, Huojun Jiang, Weiling Wang, Lingling Liu, Lu Zhou, Yuhao Zhou, Ling Liu, Huiguo Front Mol Biosci Molecular Biosciences Lung cancer is one of the main cancer types due to its persistently high incidence and mortality, yet a simple and effective prognostic model is still lacking. This study aimed to identify independent prognostic genes related to the heterogeneity of lung adenocarcinoma (LUAD), generate a prognostic risk score model, and construct a nomogram in combination with other pathological characteristics to predict patients’ overall survival (OS). A significant amount of data pertaining to single-cell RNA sequencing (scRNA-seq), RNA sequencing (RNA-seq), and somatic mutation were used for data mining. After statistical analyses, a risk scoring model was established based on eight independent prognostic genes, and the OS of high-risk patients was significantly lower than that of low-risk patients. Interestingly, high-risk patients were more sensitive and effective to immune checkpoint blocking therapy. In addition, it was noteworthy that CCL20 not only affected prognosis and differentiation of LUAD but also led to poor histologic grade of tumor cells. Ultimately, combining risk score, clinicopathological information, and CCL20 mutation status, a nomogram with good predictive performance and high accuracy was established. In short, our research established a prognostic model that could be used to guide clinical practice based on the constantly updated big multi-omics data. Finally, this analysis revealed that CCL20 may become a potential therapeutic target for LUAD. Frontiers Media S.A. 2022-04-11 /pmc/articles/PMC9035852/ /pubmed/35480896 http://dx.doi.org/10.3389/fmolb.2022.807497 Text en Copyright © 2022 Zheng, Zhang, Jiang, Wang, Liu, Zhou, Zhou and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Zheng, Pengdou
Zhang, Huojun
Jiang, Weiling
Wang, Lingling
Liu, Lu
Zhou, Yuhao
Zhou, Ling
Liu, Huiguo
Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity
title Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity
title_full Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity
title_fullStr Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity
title_full_unstemmed Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity
title_short Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity
title_sort establishment of a prognostic model of lung adenocarcinoma based on tumor heterogeneity
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035852/
https://www.ncbi.nlm.nih.gov/pubmed/35480896
http://dx.doi.org/10.3389/fmolb.2022.807497
work_keys_str_mv AT zhengpengdou establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity
AT zhanghuojun establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity
AT jiangweiling establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity
AT wanglingling establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity
AT liulu establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity
AT zhouyuhao establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity
AT zhouling establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity
AT liuhuiguo establishmentofaprognosticmodeloflungadenocarcinomabasedontumorheterogeneity